Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy
The company said 51 participants were enrolled in the biomarker group.
The del-brax biomarker group was designed for a potential accelerated approval in the US, Avidity said, adding it plans to release a regulatory update in Q2.
The company's shares were down 6% in recent trading.
Price: 29.69, Change: -1.91, Percent Change: -6.04
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.
close
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
Mid Penn Bancorp, William Penn Shareholders Approve Merger
MT Newswires - 24 minutes ago
-
ViaSat to Provide In-Flight Connectivity Aboard Riyadh Air Dreamliners
MT Newswires - 27 minutes ago
-
Carvana Insider Sold Shares Worth $10,365,942, According to a Recent SEC Filing
MT Newswires - 32 minutes ago
-
Trump signs order ending duty-free treatment for cheap shipments from China
Reuters - 33 minutes ago
-
Trump signs order ending duty-free treatment for cheap shipments from China
Reuters - 33 minutes ago
-
Global drinks maker Suntory aims to sell local to avoid tariffs, president says
Reuters - 37 minutes ago
-
Lucid Group Prices $1 Billion Private Offering of Senior Notes
MT Newswires - 37 minutes ago
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
